Summary: FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.
FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to selling hype and securities fraud.
Fierce editors discuss the FierceMadness drug name tournament, its origins, and our favorites heading into the competition. Scott Piergrossi of the Brand Institute talks us through the history of drug naming, his team's creative process, and drug-naming styles and strategies.
FierceBiotech sat down with some of the scientists, account associates and operations managers who competed in 2017's Battle of the Biotech Bands.
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit
Fraud's not that big of a deal: the Valeant story, according to Bill Ackman
Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs